Menu
Search
|

Menu

Close
X

Clovis Oncology Inc CLVS.OQ (NASDAQ Stock Exchange Global Select Market)

56.34 USD
+2.63 (+4.90%)
As of 10:09 AM EST
chart
Previous Close 53.71
Open 54.24
Volume 57,741
3m Avg Volume 409,204
Today’s High 56.36
Today’s Low 54.09
52 Week High 99.45
52 Week Low 45.42
Shares Outstanding (mil) 49.01
Market Capitalization (mil) 2,632.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.08 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY17
38
FY16
0
FY15
0
EPS (USD)
FY17
-6.450
FY16
-9.078
FY15
-9.695
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
68.29
8.67
Price to Book (MRQ)
vs sector
8.80
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
94.28
15.38
LT Debt to Equity (MRQ)
vs sector
94.28
12.01
Return on Investment (TTM)
vs sector
-78.93
13.57
Return on Equity (TTM)
vs sector
-205.06
15.19

EXECUTIVE LEADERSHIP

M. James Barrett
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Patrick Mahaffy
President, Chief Executive Officer, Director, Since 2009
Salary: $223,563.00
Bonus: $552,338.00
Daniel Muehl
Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, Since 2016
Salary: $308,879.00
Bonus: $170,799.00
Gillian Ivers-Read
Executive Vice President - Technical Operations, Chief Regulatory Officer, Since 2009
Salary: $422,300.00
Bonus: $286,443.00
Lindsey Rolfe
Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer, Since 2015
Salary: $427,500.00
Bonus: $293,625.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5500 Flatiron Pkwy Unit 100
BOULDER   CO   80301-2834

Phone: +1303.6255000

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

SPONSORED STORIES